Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
The world's largest generic drug maker, Teva Pharmaceutical Industries, has refused to fully cooperate with a Senate investigation into whether major opioid manufacturers contributed to the deadly drug epidemic, according to Sen. Claire McCaskill, D-Mo., who is leading the Senate probe. Teva has answered some of McCaskill's questions, providing the Senate committee with general information about its efforts to track and report suspicious orders for its opioid prescriptions, according to a series of letters between McCaskill and the company.
About one in 19 generic drugs sold in the U.S. during the past three years have undergone major price hikes that may be consistent with collusion, according to a wide-ranging study that comes in the middle of a sprawling Justice Department investigation into pharmaceutical price-fixing. Fideres Partners LLP, a London-based consultancy that works with law firms to bring litigation against companies, analyzed price moves in 1,670 generic drugs sold in the U.S. from 2013 to 2016.
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased American Depositary Shares of Teva between February 10, 2015 and November 3, 2016 . The case, Galmi v. Teva Pharmaceutical Industries Limited et al , No.